AAN 2023 | Blood-based biomarkers for AD diagnosis

Philip Tipton, MD, Mayo Clinic, Jacksonville, FL, discusses the use of blood-based biomarkers for Alzheimer’s Disease (AD) diagnosis. Pathogenic events of AD, such as tau aggregation, can occur decades before symptoms appear, highlighting the need for a biomarker that can diagnose asymptomatic people and be screened for at routine health check-ups. Experts also aim to identify biomarkers for the diagnosis of symptomatic patients and biomarkers that tell us how quickly AD will progress. This interview took place at the American Academy of Neurology Annual Meeting 2023 in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.